Skip to contentSkip to Braille Studio

Library / Laws / 118th Congress / House Bills / H.R. 1092

H.R. 1092

To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

Print stageDateSize⠃
Introduced in House2023-02-171.3K⠃⠗⠋